ZVRAZevra Therapeutics, Inc.
Price
+7.9%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Zevra Therapeutics, Inc. (ZVRA) reported revenue of $40M in Q2 2026 (quarter ended Jun 30, 2026), up 53% from the same quarter a year earlier. That came with a gross margin of 96% and net income of $8.8M (22% of revenue). For the full year FY2025, revenue was $106M (+351% year on year) and net income $83M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Zevra Reports Second Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
- May 6, 2026Zevra Reports First Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
- Mar 16, 2026On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.